EBS — Emergent BioSolutions Income Statement
0.000.00%
Last trade - 00:00
- $100.59m
- $849.09m
- $1.05bn
- 48
- 86
- 25
- 52
2019 December 31st | 2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K/A | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,106 | 1,555 | 1,774 | 1,118 | 1,049 |
Cost of Revenue | |||||
Gross Profit | 673 | 1,049 | 1,026 | 424 | 344 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 992 | 1,122 | 1,432 | 1,288 | 1,702 |
Operating Profit | 114 | 434 | 341 | -170 | -652 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 77.4 | 407 | 303 | -219 | -731 |
Provision for Income Taxes | |||||
Net Income After Taxes | 54.5 | 305 | 220 | -212 | -761 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 54.5 | 305 | 220 | -212 | -761 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 54.5 | 305 | 220 | -212 | -761 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.04 | 6.32 | 4.62 | -4.14 | -8.76 |